A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Trial Profile

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Lirilumab (Primary) ; Urelumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 30 May 2017 Planned End Date changed from 1 Apr 2017 to 28 Feb 2018.
    • 30 May 2017 Planned primary completion date changed from 1 Apr 2017 to 27 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top